| Ytd | -4.81% | |
| 1y | 138.17% |
| Open | 5.80 | Prev Close | 5.84 | Low | 5.65 | High | 5.87 | Mkt Cap | 1.20B |
| Vol | 1.62M | Avg Vol | 1.65M | EPS | -0.56 | P/E | -10.43 | Forward P/E | 0.41 |
| Beta | 0.24 | Short Ratio | 15.35 | Inst. Own | 104.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 5.48 | 200-d Avg | 5.33 | 1yr Est | 10.94 |
SVRA News
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded
394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted ave
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical comp
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopha
Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, wit
[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo
-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.15) per share which missed the analyst consens
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopha
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical comp
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical comp
-- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (B
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
Savara Inc. (NASDAQ: SVRA - Get Free Report) has been assigned a consensus recommendation of "Modera
VR Adviser Bought 1,059,332 shares of Savara. Post-trade, VR Adviser held 13,740,375 shares valued a
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.13) per share which met the analyst consensus
-- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare
-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$1
PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for
HC Wainwright & Co. analyst Andrew S. Fein maintains Savara (NASDAQ:SVRA) with a Buy and rais
-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufactur
Wells Fargo analyst Benjamin Burnett maintains Savara (NASDAQ:SVRA) with a Overweight and raises